DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Bruix J, Takayama T, Mazzaferro V. , et al; STORM investigators.
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol 2015;
16 (13) 1344-1354
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.